Your Messages Inbox
Your Article Summary
See Latest ArticlesResponses After Completion of Therapy Increase Pixantrone CR/CRu Rate to 24% and ORR to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial
Cell Therapeutics, 06/23/09
Cell Therapeutics, Inc. announced that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor